Project Grant K99CA293136
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$159K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $170,640 in funding to the Dana-Farber Cancer Institute, Inc. (DFCI) from July 1, 2025 to June 30, 2027. The grant supports research to investigate the role of histone cleavage in breast cancer, specifically focusing on how the KDM4C histone demethylase drives tumor growth by preventing proteolytic cleavage of the histone H3 N-terminal tail by cathepsin L. The research aims to...
This federal Project Grant award of $1,424,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The grant is supporting research to "EXPANDING THE TARGETABLE TUMOR ANTIGEN REPERTOIRE OF RENAL CELL CARCINOMA" over the performance period from August 1, 2025 to July 31, 2029. Dfci, a renowned non-profit cancer research and treatment center, will leverage...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $889,995.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (dba Dfci), a non-profit hospital and cancer research center in Boston, MA. The grant, effective June 1, 2024 through May 31, 2027, supports research to "dissect the interplay of molecular and spatial architectures with clinical states in prostate cancer." This federal funding will enable Dana-Farber to conduct...
The National Cancer Institute (NCI), under the Federal Grant Program "Cancer Research Manpower" (CFDA 93.398), awarded a Project Grant in the amount of $145,336 to the Sloan-Kettering Institute for Cancer Research located in New York. The grant, titled "Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors," will fund research focused on reprogramming hepatic macrophages to overcome the "immune-desert" phenotype of B-catenin-driven...
The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...
The Defense Health Agency awarded a $1,290,499.00 Project Grant to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "ENHANCING THE ANTITUMOR ACTIVITY OF NATURAL KILLER CELLS IN OVARIAN CANCER," is focused on conducting research to develop innovative approaches to understanding, detecting, and treating ovarian cancer. DFCI, a prestigious non-profit cancer research center, will...
The Defense Health Agency has awarded a $4,954,747 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "Novel Immunologic Discovery Platforms to Prevent Metastasis and Recurrence in Breast Cancer," will fund a four-year research project focused on developing new immunology-based approaches to prevent the spread and return of breast cancer. As a...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $314,340.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) to conduct a mechanistic study of the tumor suppressor BAP1 in clear cell renal cell carcinoma (cCRCC). The research project will run from May 1, 2024 to April 30, 2027 and aims to advance the understanding of cCRCC disease mechanisms to develop new therapies. As a leading cancer research...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant to The Johns Hopkins University to conduct research on comparative analysis of M-CSF and GM-CSF in human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The project, funded under CFDA 93.398 Cancer Research Manpower, aims to characterize differences in tumor-associated macrophage (TAM) functional attributes and their regulation between M-CSF and GM-CSF, as well as investigate...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA over a five-year period from September 1, 2024 to August 31, 2029. The award aims to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key objectives include improving...